Last $160.99 USD
Change Today +1.31 / 0.82%
Volume 571.7K
BCR On Other Exchanges
New York
As of 8:04 PM 10/30/14 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BCR) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/29/14 - $161.52
52 Week Low
02/3/14 - $125.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CR BARD INC (BCR)

cr bard inc (BCR) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BCR) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular products, including percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. The company’s urology products include Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal; catheter stabilization devices; and products for therapeutic hypothermia. It also provides specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers and other diseases and disorders. In addition, the company offers surgical specialty products, such as implanted grafts and fixation devices for hernia and soft tissue repair products; surgical sealants for intraoperative sealing of air leaks in thoracic surgery; and other products that include irrigation, wound drainage, and original equipment manufacturers’ products. It sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities, as well as through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

13,000 Employees
Last Reported Date: 02/19/14
Founded in 1907

cr bard inc (BCR) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $540.0K
Group President
Total Annual Compensation: $660.0K
Group President
Total Annual Compensation: $560.0K
Compensation as of Fiscal Year 2013.

cr bard inc (BCR) Key Developments

C. R. Bard, Inc. Reports Consolidated Unaudited Third Quarter Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Earnings Guidance for the Year of 2014; Provides Earnings Guidance for the Fourth Quarter of 2014; Reports Asset Impairment for the Quarter

C. R. Bard Inc. reported consolidated unaudited third quarter earnings results for the third quarter and nine months ended September 30, 2014. Third quarter 2014 net sales were $830.0 million, an increase of 9% over the prior-year period on both an as reported and constant currency basis. For the third quarter 2014, net income was $131.3 million and diluted earnings per share were $1.69, an increase of 41% and 47%, respectively, as compared to third quarter 2013 results. Income from operations before income taxes was $180.300 million against $119.000 million a year ago. Capital expenditures totaled $34.4 million for the quarter. For the nine-month period the company reported net sales were $2,456.400 million against $2,258.200 million a year ago. Income from operations before income taxes was $271.100 million against $110.700 million a year ago. Net income was $160.300 million or $2.04 diluted per share against $22.300 million or $0.27 diluted per share a year ago. For fourth quarter, the company is expecting constant currency sales growth between 8.5% and 9.5% with about 100 basis points of headwind from FX on a reported basis. Fourth quarter EPS is expected to be between $2.22 and $2.26. From an EPS standpoint, excluding the items affecting comparability, the company is raising full year guidance to between $8.34 and $8.38. The effective tax rate for the quarter was 25.5% and with the higher mix of U.S. income than originally projected, it now expect the effective tax rate for the full year to be around 25%, assuming the renewal of the R&D tax credit in fourth quarter of 2014. For the quarter, the company reported charge of $6.2 million pre-tax related to an asset impairment.

C. R. Bard, Inc. Announces the U.S. Food and Drug Administration Approval of the Lutonix 035 Drug Coated Balloon Catheter for Percutaneous Transluminal Angioplasty

C. R. Bard Inc. announced the U.S. Food and Drug Administration approval of the Lutonix 035 Drug Coated Balloon Catheter for percutaneous transluminal angioplasty, after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. This approval follows a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel in June 2014. The Lutonix 035 DCB--the first and only FDA-approved DCB in the U.S.-- is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries. FDA approval of the Lutonix 035 DCB was supported by results of the LEVANT 2 pivotal study, a global, prospective, single-blind, randomized, 54-site study (42 sites in the U.S. and 12 in Europe) that enrolled all patients under one protocol. At one year, the LEVANT 2 study demonstrated improved patency of the Lutonix 035 DCB compared to standard PTA: 73.5% vs. 56.8%, p<0.001 by Kaplan-Meier time-to-event analysis. It also demonstrated clinical benefits of sustained improvement in Rutherford Class and improved walking distance scores. The LEVANT 2 study followed a rigorous blinding protocol designed to reduce bias in the results to accurately and scientifically assess and compare the long-term performance of key clinical measures. The LEVANT clinical program, which includes registry data, enrolled more than 1,000 patients and demonstrated robust safety of the device comparable to PTA, including the same low rate of distal embolic events and rate of reintervention for thrombotic events.

C. R. Bard, Inc. Declares Quarterly Dividend, Payable on October 31, 2014

The board of directors of C. R. Bard Inc. declared a regular quarterly dividend of 22 cents per share on its common stock. The current indicated annual dividend rate is 88 cents per share. The dividend is payable on October 31, 2014 to shareholders of record at the close of business on October 20, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCR:US $160.99 USD +1.31

BCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $57.52 USD +0.09
Edwards Lifesciences Corp $120.28 USD +0.28
Endo International PLC $66.29 USD +0.64
Varian Medical Systems Inc $84.00 USD +0.84
View Industry Companies

Industry Analysis


Industry Average

Valuation BCR Industry Range
Price/Earnings 15.3x
Price/Sales 3.7x
Price/Book 6.5x
Price/Cash Flow 14.4x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at